Eric J. Sherman, MD, Discusses the Use of Adjuvant Capecitabine in Nasopharynx Cancer


Eric J. Sherman, MD, of Memorial Sloan Kettering Cancer Center highlights research on adjuvant capecitabine in nasopharynx cancer.

At the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, CancerNetwork® sat down with Eric J. Sherman, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, to discuss 2 phase 3 studies featuring the use of adjuvant capecitabine following cisplatin and radiation therapy in patients with advanced nasopharynx cancer (NCT02958111; NCT02143388).

In both studies, capecitabine yielded a survival benefit in patients and could possibly represent a new standard of care in this population. However, several questions still need to be answered, including as to whether adjuvant cisplatin plus 5-fluorouracil (5-FU) may be a better option and if induction chemotherapy is needed.


Two studies looked at the question of using capecitabine as adjuvant therapy for nasopharynx cancer, both looking at advanced nasopharynx cancer after cisplatin and radiation. One allowed neoadjuvant therapy, and the other did not. The one thing you saw pretty clearly is that adjuvant capecitabine led to a survival benefit—definitely a progression-free survival benefit, but it looks like an overall survival benefit, [too]. That’s really important. There’s a really big push away from adjuvant chemotherapy. This is showing that using a drug that can be given as a pill, not even [intravenous] treatment, and at reasonable doses, leads to a benefit independent of whether [the patient had] adjuvant therapy or not. These were not the high doses of capecitabine: One [study used] 1000 mg/m2 for 2 weeks on/1 week off, and the other study used just 650 mg/m2 twice a day, continued for a full year…This is something that may be a real [practice] changer in how we treat.

The question is, do we go this capecitabine route? Do we continue to do cisplatin and 5-FU as an adjuvant therapy? Do we need induction chemotherapy plus adjuvant therapy? There are still some questions that exist, but this may easily become a new standard of care for nasopharynx cancer, especially since capecitabine is an easy drug for us to get in the United States. It will be interesting to see how the FDA views both of those clinical studies.

Those are the 2 real potential game changers in the sense that they may change [our] practice [for] head and neck cancer, even in the next month or 2. [However], both of these approaches [have] some controversy and it is going to be something that everyone is going to have to discuss a lot further to figure out what their true role is in standard of therapy.


  1. Ma J, Chen YP, Sun Y, et al. Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicenter, randomized controlled trial. J Clin Oncol. 2021;39(suppl 15):6003. doi:10.1200/JCO.2021.39.15_suppl.6003
  2. Miao J, Wang L, Tan SH, et al. Adjuvant capecitabine in locoregionally advanced nasopharyngeal carcinoma: a multicenter randomized controlled phase III trial. J Clin Oncol. 2021;39(suppl 15):6005 doi:10.1200/JCO.2021.39.15_suppl.6005
Related Videos
Future meetings may address how immunotherapy, bispecific agents, and CAR T-cell therapies can further impact the AML treatment paradigm.
Treatment with revumenib appeared to demonstrate efficacy among patients with KMT2A-rearranged acute leukemia in the phase 2 AUGMENT-101 study.
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Data from the REVEAL study affirm elevated white blood cell counts and higher variant allele frequency as risk factors for progression in polycythemia vera.
Additional analyses of patient-reported outcomes and MRD status in the QuANTUM-First trial are also ongoing, says Harry P. Erba, MD, PhD.
Investigators must continue to explore the space for lisocabtagene maraleucel in mantle cell lymphoma, according to Manali Kamdar, MD.
Those with CML should discuss adverse effects such as nausea or fatigue with their providers to help optimize their quality of life during treatment.
Patients with CML can become an active part of their treatment plan by discussing any questions that come to mind with their providers.
Related Content